Find clinical trials for Lymphoma in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma

Leukemia

Non-Hodgkin Lymphoma

Lymphoid Leukemia

Diffuse Large B-Cell Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near New York, NY, USA:

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not rec...

Enrolling

Indolent Non-hodgkin Lymphoma

Marginal Zone Lymphoma

Drug: Obinutuzumab

Drug: Glofitamab

Phase 2

Reid Merryman, MD

New York, New York, United States and 2 other locations

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ...

Enrolling

Refractory Plasmablastic Lymphoma

Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Drug: Belantamab Mafodotin

Phase 2

Jacob Soumerai, MD

New York, New York, United States and 2 other locations

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma...

Active, not recruiting

Relapsed Follicular Lymphoma

Refractory Follicular Lymphoma

Drug: Venetoclax

Drug: Ibrutinib

Phase 1, Phase 2

Georgetown University

Hackensack, New Jersey, United States and 2 other locations

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators hypot...

Enrolling

Follicular Lymphoma

Drug: Mosunetuzumab

Drug: Tazemetostat Pill

Phase 2

Weill Cornell Medicine (WCM)

New York, New York, United States

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling

Hodgkin Lymphoma, Adult

Hodgkin Lymphoma

Drug: MT-601

Phase 1

Marker Therapeutics

New York, New York, United States and 6 other locations

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...

Enrolling

Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)

Drug: ARV-393

Phase 1

Arvinas

New York, New York, United States and 13 other locations

DS-3201b in Participants With Lymphomas

DS-3201b is an experimental drug that is being investigated in clinical research.Adults with non-Hodgkin lymphoma (NHL) may be able to join ...

Active, not recruiting

Lymphoma, Malignant

Non-hodgkin Lymphoma

Drug: DS-3201b

Phase 1

Daiichi Sankyo

New York, New York, United States and 20 other locations

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling

Lymphoma, Non-Hodgkin

Drug: Obinutuzumab

Drug: CC-99282

Phase 1, Phase 2